An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor

Journal of Rheumatology

Volumn 35, Issue 11, 2008, Pages 2119-2128

  Brahn, Ernest ^a   Banquerigo, Mona L ^a   Lee, John K ^a   Park, Eun J ^b   Fogler, William E ^b   Plum, Stacy M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ENTREMED INC   (United States)

Author keywords

2 Methoxyestradiol; Angiogenesis inhibition; Animal disease models; Endothelial cells; Vascular endothelial growth factor

Indexed keywords

2 METHOXYESTRADIOL; BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTHRITIS; ARTICLE; BLOOD VESSEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; INVOLUTION; MICROSCOPY; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROPHYLAXIS; SYNOVIUM;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; COLLAGEN; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; ESTRADIOL; FIBROBLAST GROWTH FACTOR 2; GASTRIC LAVAGE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFUSION PUMPS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED STRAINS; SYNOVIAL MEMBRANE; TUBULIN MODULATORS; VON WILLEBRAND FACTOR;

EID: 56449110050     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080302     Document Type: Article

References (49)

1. Nagashima M, Asano G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 2000;27:2339-42.
2. Fox RI, Kang H. Rheumatoid arthritis. In: McCarty D, Koopman W, editors. Arthritis and allied conditions. 12th ed. Philadelphia: Lea & Febiger; 1993:263-78.
3. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992;51:919-25.
4. Walsh DA. Angiogenesis and arthritis. Rheumatology Oxford 1999;38:103-12.
5. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
6. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 2003;6:355-61.
7. Pribluda VS, Gubish ER Jr, LaVallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000;19:173-9.
8. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van WC. 2-Methoxyestradiol inhibits hypoxia-inducible factor 1 alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 2004;10:8665-73.
9. LaVallee TM, Zhan XH, Johnson MS, et al. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003;63:468-75.
10. Gao N, Rahmani M, Dent P, Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005;24:3797-809.
11. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005;65:9021-8.
12. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
13. Brahn E. Animal models of rheumatoid arthritis. Clues to etiology and treatment. Clin Orthop Relat Res 1991;265:42-53.
14. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994;157:291-9.
15. Brahn E, Trentham DE. Antigen-specific suppression of collagen arthritis by adoptive transfer of spleen cells. Clin Immunol Immunopathol 1984;31:124-31.
16. Brahn E, Trentham DE. Effect of antithymocyte serum on collagen arthritis in rats: evidence that T cells are involved in its pathogenesis. Cell Immunol 1984;86:421-8.
17. Brahn E, Helfgott SM, Belli JA, et al. Total lymphoid irradiation therapy in refractory rheumatoid arthritis. Fifteen- to forty-month followup. Arthritis Rheum 1984;27:481-8.
18. Jiang Y, Zhao JJ, Medicherla S, et al. P38a MAP kinase inhibition of rat collagen-induced arthritis: semi-quantitative assessment of inflammatory arthritis by 3D micro CT imaging [abstract]. Arthritis Rheum 2004;50 Suppl:S366.
19. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53:523-37.
20. Brahn E, Trentham DE. Experimental synovitis induced by collagen-specific T cell lines. Cell Immunol 1989;118:491-503.
21. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
22. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-20.
23. Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ, Brenchley PE. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor: specific up-regulation by tumour necrosis factor-alpha in synovial fluid. Clin Exp Immunol 1999;117:171-6.
24. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor: accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
25. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30:260-8.
26. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000;191:426-33.
27. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
28. Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995;22:1624-30.
29. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with endstage, destructive rheumatoid arthritis. Ann Rheum Dis 2003;62:635-8.
30. Scola MP, Imagawa T, Boivin GP, et al. Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice. Arthritis Rheum 2001;44:794-801.
31. Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007;3:434-42.
32. Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999;115:176-82.
33. Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 2006;103:159-66.
34. Ryu S, Lee JH, Kim SI. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006;25:16-20.
35. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
36. Huang SP, Wu MS, Shun CT, et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004;11:517-27.
37. Feurino LW, Zhang Y, Bharadwaj U, et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther 2007 Jul 22. [Epub ahead of print]
38. Stevens CR, Blake DR, Merry P, Revell PA, Levick JR. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum 1991;34:1508-13.
39. Dingle JT, Thomas DP. In vitro studies on human synovial membrane; a metabolic comparison of normal and rheumatoid tissue. Br J Exp Pathol;37:318-23.
40. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1 alpha and 2 alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003;13:493-501.
41. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998;273:6417-23.
42. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
43. Becker CM, Rohwer N, Funakoshi T, et al. 2-Methoxyestradiol inhibits hypoxia-inducible factor-1 alpha and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008;172:534-44.
44. Yamashita A, Yonemitsu Y, Okano S, et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002;168:450-7.
45. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002;29:230-9.
46. Strunk J, Bundke E, Lange U. Anti-TNF-alpha antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int 2006;26:252-6.
47. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004;50:1636-41.
48. Josefsson E, Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 1997;40:154-63.
49. Issekutz AC, Sapru K. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: An effect independent of an anti-angiogenic action. Int Immunopharmacol 2008;8:708-16.